Drugs / TG-0054
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00822341 | Apr 2008 → May 2009 | — | GPCR Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT02104427 | Feb → Nov 2015 | Hodgkins lymphoma, non-Hodgkin lymphoma, plasma cell myeloma | GPCR Therapeutics, Inc. | Completed | Met primary |
| Phase 2 | NCT01458288 | Oct 2012 → Jul 2013 | Hodgkins lymphoma, non-Hodgkin lymphoma, plasma cell myeloma | GPCR Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01018979 | Feb 2010 → Oct 2011 | Hodgkins lymphoma, non-Hodgkin lymphoma, plasma cell myeloma | GPCR Therapeutics, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-10-26 | GPCR Therapeutics, Inc. | Results GPCR Therapeutics Announces Publication on Improving Hematopoietic Stem Cell Mobilization Using Propranolol with GPC-100 gpcr.co.kr ↗
The paper shows that the company’s lead small molecule asset, GPC-100, a novel CXCR4 antagonist and a potent hematopoietic stem cell (HSC) mobilizer, when combined with the beta-adrenergic receptor blocker propranolol, results in a significant increase in circulating HSCs in mice. |
| 2023-08-15 | GPCR Therapeutics, Inc. | Results GPCR Therapeutics Demonstrates Clinical Improvement in Mobilization of Hematopoietic Stem Cells Using GPC-100/Burixafor in Clinical Pharmacology in Drug Development gpcr.co.kr ↗
The results demonstrate that the company’s lead small molecule asset, GPC-100/burixafor, is generally safe and well tolerated. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-10-26 | GPCR Therapeutics, Inc. | GPCR Therapeutics Announces Publication on Improving Hematopoietic Stem Cell Mobilization Using Propranolol with GPC-100 gpcr.co.kr ↗ |
| 2023-08-15 | GPCR Therapeutics, Inc. | GPCR Therapeutics Demonstrates Clinical Improvement in Mobilization of Hematopoietic Stem Cells Using GPC-100/Burixafor in Clinical Pharmacology in Drug Development gpcr.co.kr ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TG-0054 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02104427 ↗ |
| Action | Inhibit | “TG-0054 is a CXCR4 antagonist” NCT00822341 ↗ |
| Route | Intravenous | “via 15 min IV infusion” NCT00822341 ↗ |
| Target | CXCR4 | “TG-0054 is a CXCR4 antagonist” NCT00822341 ↗ |